Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?

Autor: Hamid MA; Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria., Pammer LM; Department of Gastroenterology and Hepatology, Medical University of Innsbruck, Innsbruck, Austria., Lentner TK; Clinical Department for Internal Medicine, University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, St. Poelten, Austria., Doleschal B; Department of Internal Medicine I for Hematology With Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz, Linz, Austria.; Medical Faculty, Johannes Kepler University Linz, Linz, Austria., Gruber R; Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria., Kocher F; Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria., Gasser E; Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria., Jöbstl A; Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria., Seeber A; Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria., Amann A; Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. arno.amann@tirol-kliniken.at.
Jazyk: angličtina
Zdroj: Current oncology reports [Curr Oncol Rep] 2024 Oct; Vol. 26 (10), pp. 1258-1270. Date of Electronic Publication: 2024 Jul 30.
DOI: 10.1007/s11912-024-01583-w
Abstrakt: Purpose of Review: This review will explore various strategies to rendering MSS mCRCs susceptible to ICI. Moreover, we will provide an overview of potential biomarkers that may aid to better patient selection, and discuss ongoing efforts in this area of research.
Recent Findings: Colorectal cancer (CRC) ranks among the top three most common cancers worldwide. While significant advances in treatment strategies have improved the prognosis for patients in the early stages of the disease, treatment options for metastatic CRC (mCRC) remain limited. Although immune checkpoint inhibitors (ICI) have revolutionized the treatment of several malignancies, its efficacy in mCRC is largely confined to patients exhibiting a high microsatellite instability status (MSI-H). However, the vast majority of mCRC patients do not exhibit a MSI-H, but are microsatellite stable (MSS). In these patients ICIs are largely ineffective. So far, ICIs do not play a crucial role in patients with MSS mCRC, despite the promising data for inducing long-term remissions in other tumour entities. For this reason, novel treatment strategies are needed to overcome the primary resistance upon ICI in patients with MSS.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: